Regeneron Pharmaceuticals Inc (REGN)
Return on total capital
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 5,187,200 | 4,911,400 | 5,032,000 | 4,835,100 | 5,032,400 | 4,654,200 | 4,113,100 | 4,272,300 | 4,448,500 | 4,845,000 | 4,719,500 | 4,918,200 | 6,093,600 | 6,399,300 | 9,190,200 | 9,383,100 | 8,105,000 | 7,298,800 | 4,460,200 | 3,867,300 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 30,957,800 | 29,938,900 | 29,387,600 | 29,353,600 | 29,325,900 | 28,205,800 | 26,991,100 | 25,973,100 | 24,904,400 | 24,017,900 | 23,495,200 | 22,664,000 | 21,438,800 | 20,687,800 | 19,914,700 | 18,768,800 | 17,258,000 | 15,127,300 | 11,977,000 | 11,025,300 |
| Return on total capital | 16.76% | 16.40% | 17.12% | 16.47% | 17.16% | 16.50% | 15.24% | 16.45% | 17.86% | 20.17% | 20.09% | 21.70% | 28.42% | 30.93% | 46.15% | 49.99% | 46.96% | 48.25% | 37.24% | 35.08% |
September 30, 2025 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $5,187,200K ÷ ($—K + $30,957,800K)
= 16.76%
Peer comparison
Sep 30, 2025
Company name
Symbol
Return on total capital
Regeneron Pharmaceuticals Inc
REGN
16.76%
Arrowhead Pharmaceuticals Inc
ARWR
17.83%
Biomarin Pharmaceutical Inc
BMRN
11.39%